Efficiency of rEPO therapy in hemodialysis patients with chronic renal failure and oncohaematologic diseases on HD
Abstract
The purpose of the work was to study the efficiency of rEPO therapy («Eprex») in haemodialysis patients with chronic renal failure (CRF). Patients were subdivided into three groups: group I included patients with CRF, group II included patients with CRF and oncohaematologic diseases, group III was the control group. The treatment was carried out up to 6 months. Patients of group I achieved and maintained hemoglobin (Hb) level of at least 120 g/dl. As expected, Hb level increased in group II, but did not change in the control group. The «Eprex» therapy was associated with significant increase in Hb and decrease in transfusion requirements. Recent studies have confirmed that anemia correction in patients with CRF may slow down the progression of heart failure and improve quality of life.
About the Authors
N. V. Purlo
Гематологический научный центр РАМН, г. Москва
Russian Federation
Russian Federation
L. S. Birjukova
Гематологический научный центр РАМН, г. Москва
Russian Federation
Russian Federation
G. I. Kozinets
Гематологический научный центр РАМН, г. Москва
Russian Federation
Russian Federation
References
1. Козинец Г.И., Макарова В.А. Исследование системы крови в клинической практике. М.: Триада-Х, 1997: 480.
2. Луговская С.А., Морозова В.Т., Почтарь М.Е., Долгов В.В. Эритропоэз. Лабораторная гематология 2002: 11-16.
3. Павлов А.Д., Морщакова Е.Ф. Синдром влияния неадекватной продукции эритропоэтина на анемию. Гематол. и трансфузиол. 1999; 44: 30-32.
4. Самойлов М.В. Морфофункциональная характеристика эритроцитов при хронической почечной недостаточности, гнойной интоксикации и экстракорпоральной детоксикации: Автореф. дисс. … докт. мед. наук. М.: 2000: 46.
5. Сарычева Т.Г. Морфофункциональная характеристика эритрона при гематологических заболеваниях и ХПН. М.: 2000: 40.
6. Фишер Дж. Эритропоэтин: механизмы гипоксической регуляции. Гематол. и трансфузиол. 1997; 42: 19-22.
7. Шостка Г.Д. Анемия при почечной недостаточности. Нефрология 1997; 1; 4: 12-18.
8. Albertazzi A. Once-weekly epoetin-beta in renal anemia: the clinical evidence. Contrib Nephrol 2002: 408-411.
9. Bommer J., Kugel M., Schoeppe W. et al. Dose-related effects of recombinant human erythropoietin on erythropoesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib. Nephrol 1998: 85-93.
10. Eckardt K.U. Patophysiology of renal anemia. Clin Nephrol 2000; 53: 2-8.
11. Eschbach J.W. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1998; 35: 134-148.
12. Furuland H., Linde T., Ahlmen J. et al. A randomized controlled trial of Hb normalization with epoetin alfa in predialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361.
13. Gadegbeku C., Freeman V., Agodoa L. Racial disparities in renal replacement therapy. J Nat Med Assoc 2002: 45-54.
14. Lebel M., Kingma I., Grose J.H., Langlois S.L. Haemodynamic and hormonal changes during erythropoietin therapy in haemodialysis patients. J Am Soc Nephrol 1998; 9: 97-107.
15. Madore F., Lowrie E.G., Brugnara C., Lew N.L., Lazarus J.M., Bridges K., Owen W.F. Anaemia in haemodialysis patients: variable affecting this outcome predictor. J am Soc Nephrol 1997; 8: 1921-1929.
16. Paganini E.P., Garcia J., Abdulhadi M., Lathim D., Giesman J., Weick J.K. The anemia of chronic renal failure. Overview and early erythropoietin experience. Cleve Clin J Med 1989; 56: 79-86.
17. Stivelman J.C. Resistance to recombinant human erythropoietin therapy. Semin Nephrol 1989; 9: 8-11.
18. Sundal E., Businger J., Bougton K. Recombinant human erythropoietin (r-huEPO). A comprehensive clinical review. Drugs of Today 1989; 25; 12: 799-816.
19. Subota J.T. Erythroроietin treatment of end stage renal disease: North American and Japanese experience. In: Garnic (ed): Erytropoietin in clinical applications. 1990: 183-219.
20. Suthanthiran M. Renal transplantation: reaping the rewards of biomedical research. Curr Opin Nephrol Hypertens 2000: 597-598.
21. Zachee P. Controversies in selection of epoetin dosages. Issues an answers. Drugs 1995; 49: 536-547.
Review
For citations:
Purlo N.V., Birjukova L.S., Kozinets G.I. Efficiency of rEPO therapy in hemodialysis patients with chronic renal failure and oncohaematologic diseases on HD. Nephrology and Dialysis. 2004;6(4):325-330. (In Russ.)
Views:
13
Email this article 